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Recent studies in mice using genetic approaches have
shed new light on the physiological effects of
1,25-dihydroxyvitamin D (1,25(OH)2D) and the vitamin D
receptor (VDR) in skeletal and mineral homeostasis, and on
their interaction with calcium. These studies in mice with
targeted deletion of the 25-hydroxyvitamin D-1a-hydroxylase
(1a(OH)ase), and of the VDR or of double mutants, have
shown the discrete effects of calcium in inhibiting
parathyroid hormone secretion and in enhancing bone
mineralization, but overlapping effects of calcium and
1,25(OH)2D on inhibiting parathyroid growth and on normal
development of the cartilaginous growth plate. The
1,25(OH)2D/VDR system is essential, however, in enhancing
intestinal calcium absorption and in optimally increasing
osteoclastic activation. In addition, the 1,25(OH)2D/VDR
system has important anabolic effects on bone, thus defining
a dual role for this system in bone turnover. These studies are
revealing functions of the vitamin D/VDR system which have
relevance for new concepts of the pathophysiology of renal
bone disease and, in particular, of the adynamic bone
disorder, and for the development of new analogs of the
active form of vitamin D, which have less calcemic activity
and greater skeletal anabolic effects.
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Circulating concentrations of the active metabolite of vitamin
D, 1,25-dihydroxyvitamin D (1,25(OH)2D), derive from 1a-
hydroxylation of 25-hydroxyvitamin D (25(OH)D) by the
renal mitochondrial enzyme, 25(OH)D-1a-hydroxylase
(1a(OH)ase).1–3 1,25(OH)2D circulates bound to the vitamin
D binding protein. After being taken up by target cells and
bound to intracellular binding proteins, the sterol interacts
with the vitamin D receptor (VDR), a member of the nuclear
receptor superfamily.4 In the nucleus of target cells, the
ligand-activated VDR heterodimerizes with the retinoid X
receptor and the dimer binds to response elements on target
genes.5 Coregulators are recruited to link the dimer to the
basal transcriptional machinery and thereby modulate gene
transcription. Differential interactions with the binding
proteins involved in transport or intracellular chaperoning
of 1,25(OH)2D3, mobilization of discrete VDR coregulators,
differential effects on VDR turnover, or distinct rates or
pathways of elimination of vitamin D analogs are among the
mechanisms which contribute to the specific actions of newer
vitamin D analogs. In addition to the canonical pathway of
action described above, a number of pathways involving
rapid, nongenomic effects have been described. These include
interaction of the ligand with a membrane receptor, either a
novel receptor or the known VDR, thereby activating cell
signaling pathways.6,7 Both the VDR and extrarenal
1a(OH)ases have been described in a variety of tissues,
beyond those related to skeletal and mineral homeostasis,
implicating vitamin D action in a broad range of physiologic
functions.
RENAL OSTEODYSTROPHY
Circulating concentrations of 1,25(OH)2D have profound
effects on parathyroid function, mineral metabolism, and
skeletal function, which are severely disordered in chronic
kidney disease (CKD). 1,25(OH)2D synthesis is impaired in
CKD in part due to suppression of the 1a(OH)ase by
retained phosphate and in part because of loss of renal
parenchyma. As a result, low levels of calcitriol develop in
stage 3 CKD. This results in reduced calcium absorption,
which, with hyperphosphatemia due to impaired renal
tubular function and decreased bone formation, leads to
hypocalcemia. Hypocalcemia, low 1,25(OH)2D, and phos-
phate retention can lead to the development of secondary
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hyperparathyroidism and disordered skeletal remodeling,
which may be accentuated by decreased levels of VDR and
diminished levels of the calcium sensing receptor in
hyperplastic parathyroid tissue. The skeletal consequence of
secondary hyperparathyroidism is a disorder of bone
remodeling referred to as osteitis fibrosa. Secondary hyper-
parathyroidism also contributes to the reduced longitudinal
bone growth that occurs in CKD, affecting the pediatric
population due to effects of the derangements of Ca, Pi, and
vitamin D on the cartilaginous growth plate.
GENETIC ANALYSIS OF THE 1,25(OH)2D/VDR SYSTEM AS A
PROBE FOR FUNCTIONALITY
Several ‘knockout’ mouse models, with targeted disruption of
either the 1a(OH)ase8,9 or the VDR10–12 gene have been
generated (1a(OH)ase/ and VDR/ mice, respectively).
These represent murine models of the inherited human
disorders, vitamin D-dependent rickets type I and type II,
respectively.13,14 We have used these models and double null
mutants (1a(OH)ase/VDR/) to examine the effects of
the 1,25(OH)2D/VDR system on mineral, parathyroid, and
skeletal homeostasis.15 The study of the mechanisms under-
lying the 1,25(OH)2D- and VDR-deficient phenotypes in
these mouse mutants has been facilitated by the correction of
the hypocalcemia, which these animals exhibit, by a ‘rescue’
diet containing high concentrations of calcium, phosphorus,
and lactose.16–18 These genetic models and the environmental
manipulations of the models have therefore provided
powerful probes to dissect in vivo the discrete and over-
lapping contributions of vitamin D, calcium, and parathyroid
hormone (PTH) to the endocrine control of skeletal and
mineral metabolism.19
Effects on calcium homeostasis and parathyroid function
Optimal dietary calcium absorption in the 1a(OH)ase/
and the VDR/ mice required an intact 1,25(OH)2D/VDR
system. In more recent studies in young 1a(OH)ase/ mice
and mice with targeted ablation of the PTH gene (PTH/),
we found that both 1,25(OH)2D and PTH could indepen-
dently and co-operatively modulate renal calcium transpor-
ters including the luminal epithelial channel transient
receptor potential-vanilloid-5 (TRPV5), the intracellular
calcium-binding proteins calbindin-D28K and calbindin-
D9K, and the basolateral membrane sodium–calcium ex-
changer, NCX1.20 These results are consistent with the
actions of 1,25(OH)2D reported in other 1a(OH)ase
/
models.21 In the 1a(OH)ase/ and VDR/ models,
secretion of intact PTH was modulated primarily by ambient
serum calcium in that normalization of serum calcium with
the rescue diet normalized circulating PTH even in the
absence of 1,25(OH)2D or the VDR. Nevertheless, the
parathyroid gland hyperplasia, which the mutants exhibited,
persisted when calcium alone was normalized. The combina-
tion of normal extracellular calcium and 1,25(OH)2D
(apparently independently of the VDR) was required for
normalization of parathyroid gland size. The results indicate
that calcium cannot entirely substitute for deficient vitamin
D in maintaining parathyroid homeostasis, and that the two
agents act co-operatively in modulating parathyroid cell
proliferation.
Development of the cartilaginous growth plate
On a normal- or high-calcium lactose-free intake, all three
hypocalcemic mutant mouse models, the 1a(OH)ase/,
VDR/, and 1a(OH)ase/VDR/ mice, develop charac-
teristic skeletal rachitic changes of enlarged and distorted
cartilaginous long bones with widened hypertrophic
zones.8–10,11,15,18 These abnormalities appear less severe in
VDR/ mice with elevated endogenous 1,25(OH)2D levels
than in the other two mutants, suggesting that 1,25(OH)2D
may modulate cartilage function independently of the VDR.
Nevertheless, 1,25(OH)2D per se cannot normalize the
growth plate if hypocalcemia is not normalized and,
conversely, elimination of hypocalcemia with the rescue diet
does not completely normalize the growth plate in the mouse
models that have deficient endogenous 1,25(OH)2D. Conse-
quently, both calcium and 1,25(OH)2D together appear
necessary for normal development of the cartilaginous
growth plate, analogous to the effect on parathyroid growth.
Previous studies in double-null mutants of the VDR and of
the retinoid X receptor g have suggested the existence of a
novel VDR in the cartilaginous growth plate with which
1,25(OH)2D may interact.
22 In addition, rapid, nongenomic
effects have been reported in cartilage cells.6,7 Our findings
are consistent with one or other or both of these possibilities.
Skeletal mineralization
Mineralization of both cartilage and bone is severely
impaired in all mutants (the 1a(OH)ase/, VDR/, and
1a(OH)ase/, VDR/ models) that are hypocalcemic on
either a lactose-free-normal or high-calcium intake.15 How-
ever, cartilage mineralization and bone mineralization are
normalized in all models when hypocalcemia is eliminated by
the rescue diet. Administration of exogenous 1,25(OH)2D3
normalizes mineralization only when serum calcium is
normalized, that is, in the 1a(OH)ase/ model.15 Conse-
quently, the major determinant of skeletal mineralization
appears to be the ambient concentration of extracellular
calcium (and phosphate) and the 1,25(OH)2D/VDR system
appears to play no direct role in this process.
Bone remodeling
Osteoblast numbers, bone formation, and bone volume are
markedly increased in all hypocalcemic animals
(1a(OH)ase/, VDR/, and 1a(OH)ase/ VDR/ mice)
on either a lactose-free, normal-calcium intake,8–10 or a
lactose-free, high-calcium intake.15 This appears to be due to
the anabolic effect of PTH, which is markedly elevated in
association with the severe secondary hyperparathyroidism in
these animals. Increased serum alkaline phosphatase reflects
the increased osteoblastic stimulation by PTH and is
normalized when PTH is normalized by eliminating the
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secondary hyperparathyroidism. The increased bone volume
is largely due to increased unmineralized bone matrix
however, as a result of the ambient hypocalcemia. Interest-
ingly, a sustained elevation of increased PTH is generally
associated with increased osteoclastic bone resorption as well
as increased bone formation. Nevertheless, osteoclast number
and resorbing surface are not appreciably elevated in these
models compared to wild-type, suggesting an inappropriate
response to the increased PTH. Furthermore, in our
studies,15 a decrease in the average osteoclast size was seen
in the 1,25(OH)2D- and/or VDR-deficient mutant animals
with secondary hyperparathyroidism. This suggests that there
is uncoupling of bone turnover in the presence of a defective
1,25(OH)2D/VDR system and the relatively low resorption
may contribute, with increased osteoblast activity, to the
increased bone volume. Indeed, previous studies with
osteoclast-generating models in vitro have shown that
osteoblastic cells from VDR/ mice in culture with normal
spleen cells could not sustain 1,25(OH)2D-stimulated
osteoclast production, although PTH could.23 Therefore,
although PTH and local modulators of bone resorption may
sustain a normal level of osteoclastic resorption in these
models, an intact 1,25(OH)2D/VDR system is required for an
optimal osteoclastic response to increased PTH.
In view of the fact that osteoclast/chondroclast production
at the chondro-osseous junction may also be defective,
diminished removal of hypertrophic chondrocytes may occur
in this region, leading to altered cartilage growth plate
remodeling. Therefore, the enlargement of the cartilaginous
growth plate, and notably the hypertrophic zone, may also be
in part due to reduced activity of the 1,25(OH)2D/VDR
system on the chondroclast/osteoclast system.17
In our studies we also found that in all three mutant
models, that is, in the absence of 1,25(OH)2D, VDR, or both
1,25(OH)2D and VDR, when serum calcium was normalized
by the rescue diet and secondary hyperparathyroidism was
prevented, osteoblast numbers, mineral apposition rate, and
bone volume were suppressed below the levels seen in wild-
type mice.15 This showed that, when the 1,25(OH)2D/VDR
system is deficient in the presence of normal PTH and
normal calcium, a requirement of the 1,25(OH)2D/VDR
system for baseline bone anabolism can be unmasked. The
1,25(OH)2D/VDR system therefore appears to exert an
anabolic effect, which is necessary to sustain basal bone-
forming activity. This inhibition of bone formation was not
previously observed in either VDR/ or 1a(OH)ase/ mice
on the rescue diet and may reflect the older age of our mice at
the time of analysis. Furthermore, other studies have also
pointed to an anabolic effect of 1,25(OH)2D,
24–26 supporting
the observations in our model. Our studies therefore suggest
that 1,25(OH)2D may exert effects on both bone resorption
and bone formation analogous to those of PTH.
Comparative skeletal effects of 1,25(OH)2D and PTH
To better understand the relative contributions of
1,25(OH)2D and PTH to bone anabolism, we recently
compared 1a(OH)ase/ mice to PTH/ mice.20 Reduced
osteoblastic bone formation in the metaphyseal region was
seen in both mutants, confirming our findings of a
requirement for endogenous 1,25(OH)2D as well as for
endogenous PTH for bone anabolism. PTH deficiency
however caused only a slight reduction in long bone length
but a more marked reduction in trabecular bone volume in
these models, whereas 1a(OH)ase ablation caused a smaller
reduction in trabecular bone volume but a significant
decrease in bone length. Therefore, although both
1,25(OH)2D and PTH can affect long bone growth and
trabecular bone growth, PTH plays a predominant role in
appositional bone growth, whereas 1,25(OH)2D acts pre-
dominantly on endochondral bone formation. We subse-
quently confirmed these findings by administering exogenous
1,25(OH)2D3 (calcitriol) and PTH to these animals.
27
Consequently, both 1,25(OH)2D and PTH exert anabolic
effects that are discrete but complementary.
Overall therefore, these genetic models have provided
important new insights into the role of the active form of
vitamin D in mineral and skeletal homeostasis (Table 1). The
actions on parathyroid growth, on regulating the develop-
ment of the epiphyseal growth plate, and on regulating bone
formation seem of particular relevance for the mineral and
skeletal alterations which occur in both pediatric and adult
kidney disease, and improved knowledge of the physiology of
the vitamin D system may lead to improved design and use of
vitamin D analogs in CKD.
VITAMIN D ANALOG THERAPY IN CKD
Calcitriol and adynamic bone disorder
In patients with CKD, placebo-controlled trials have
demonstrated that administration of daily oral calcitriol
Table 1 | Effects of 1,25(OH)2D, calcium, and PTH on selected
parameters of mineral and skeletal metabolism based on in














Endochondral bone formation ++
Bone mineralization +
Appositional bone formation + ++
Bone volume +
Bone resorption – osteoclastic
activity
+ +
Bone formation – osteoblastic
activity
+ +
1a-(OH)ase activity   +
24-(OH)ase activity + + 
a+, stimulatory effect; inhibitory effect; no symbol indicates no effect or effect not
examined.
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reduced PTH levels and improved bone biopsy findings.28,29
Concerns regarding the safety of such therapy related to
deterioration of kidney function were addressed, demonstrat-
ing that the rate of decline in glomerular filtration rate did
not differ between placebo- and vitamin D-treated pa-
tients.28,30 Nevertheless, despite oral daily regimens of
calcitriol or alfacalcidol, secondary hyperparathyroidism
remained the predominant bone lesion observed, especially
in dialysis patients and the younger age groups.31–33
The introduction of intravenous calcitriol was associated
with marked reductions in PTH levels and bone turnover in
hemodialysis patients.34 Oral intermittent regimens were
subsequently shown to be as effective despite the greater
bioavailability of intravenous calcitriol.35–37 Some authors
concluded from their studies of intermittent calcitriol
therapy that the reduction in bone formation rate appeared
to be greater than that of PTH levels.38,39 Such findings led
authors to suggest a direct negative effect of vitamin D on
osteoblastic activity. In patients on peritoneal dialysis, high-
dose intermittent oral or intraperitoneal calcitriol therapy
was associated with a marked decline in bone formation
rates, leading to the development of the adynamic bone
disorder (ABD) in a substantial proportion of the pa-
tients.38,40,41 Calcium-based phosphate binders were given to
all of the patients and the serum calcium levels increased
during the period of the studies. This prompted the
conclusion that both the use of active vitamin D sterols
and the exogenous calcium load played a role in the
pathogenesis of the ABD (Figure 1).41
Alternative pathogenic mechanisms of the ABD have,
however, been recently demonstrated in translational studies,
which are in agreement with the genetic analysis of the
1,25(OH)2D/VDR system functionality in bone remodeling.
Lund et al.42 have shown in mice subjected to renal ablation
and proportional reduction in dietary phosphorus with
maintenance of normal Ca, Pi, PTH, and calcitriol levels that
the ABD resulted. These data strongly indicate that renal
injury directly impairs skeletal anabolism. The data were
confirmed in another animal model with the metabolic
syndrome of obesity, hypertension, dyslipidemia, and type II
diabetes (low-density lipoprotein receptor-deficient mice fed
high-fat/cholesterol diets), where induction of CKD resulted
in the ABD despite secondary hyperparathyroidism.43 Thus,
reinterpretation of the human studies is possible, with the
conclusion that reversal of secondary hyperparathyroidism
uncovers the effect of renal disease on the skeleton. This
produces the concept that secondary hyperparathyroidism is
an adaptation to loss of skeletal anabolism produced by
kidney disease, especially early in CKD before hyperpho-
sphatemia and calcitriol deficiency are uniformly detected.
Calcitriol and extra-skeletal calcification
Calcitriol therapy increases intestinal calcium and phos-
phorus absorption, with the subsequent development of
hypercalcemia and hyperphosphatemia in some patients with
CKD. The increase in calcium–phosphorus product limits
therapy with vitamin D analogs and may play a role in the
development of extraskeletal and vascular calcification.44
Milliner et al.45 found postmortem evidence of soft tissue and
vascular calcification in 60% of 120 children with end-stage
kidney disease.45 The strongest correlation with calcinosis
among the calcium phosphate (Ca-PO4) product, sex, age of
onset of kidney disease, and vitamin D therapy was with the
latter. Current evidence suggests that abnormalities in Ca-
PO4 mineral metabolism, use of calcium-containing phos-
phate binders, and therapy with active vitamin D sterols play
a role in the development of vascular calcification.46,47
Vascular calcification and hyperphosphatemia are indepen-
dent risks for cardiovascular disease and excess mortality in
the end-stage kidney disease (ESKD) population.48–51 Even
among the young ESKD patients, cardiovascular disease is the
leading cause of death and a substantial proportion of such
patients demonstrate evidence of coronary artery calcifica-
tion.52 The role of calcitriol and active vitamin D analogs in
the pathogenesis of vascular calcification is unclear despite
the discussion above. Several epidemiologic studies suggest
that active vitamin D analog therapy is associated with
reduced vascular calcification,53,54 while translational stu-
dies55,56 and studies in vitro57,58 indicate that they may be
causative of vascular calcification.
Vitamin D analogs
New vitamin D analogs have been designed to minimize the
increase in intestinal calcium and phosphorus absorption
while continuing to suppress hyperparathyroidism as effe-
ctively as calcitriol at least in animal studies.59–61 Three
new vitamin D analogs are available for clinical use in CKD:
22-oxacalcitriol (OCT) in Japan, and 19-nor-1,25-dihydrox-
yvitamin D2 (paricalcitol) and 1a-hydroxyvitamin D2
(doxercalciferol) in the USA. Interestingly, in a series of repeat
bone biopsies, OCT did not decrease bone formation rates.62
Renal injury
Pathogenesis of the adynamic bone disorder in CKD
Loss of skeletal Secondary
hyperparathyroidismanabolism
↓ Osteoclast # ↑ Osteoclast #
↑ Osteoclast↓ Near-normal osteoclast
↓ Bone formation rate ↑ Bone formation
activity activity
Clinical therapy
Active Vit D analogs/
Ca-based PO4 binders
↑
Figure 1 | In CKD, renal injury produces loss of skeletal anabolism
possibly through decreases in bone morphogenetic protein
influence. The reduction in the bone mineralization front represents
a decrease in the exchangeable phosphorus pool contributing to
stimulation of PTH secretion and secondary hyperparathyroidism.
Thus, the latter, especially early in CKD, is an adaptation to loss of
skeletal anabolism. When the adaptation is removed by correction of
secondary hyperparathyroidism using active vitamin D analogs and
Ca-based PO4 binders, the effect of kidney disease on the skeleton is
uncovered – the ABD.
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Studies with 19-nor-1,25-dihydroxyvitamin D2 demonstrate
fewer episodes of hypercalcemia and a lower calcium-
phosphorus product with equal suppression of PTH during
8 weeks of the study.63,64 The long-term effects of these
therapeutic approaches have yet to be determined on vascular
calcification and mortality. However, in a large dialysis
cohort analyzed retrospectively, greater survival rates were
described in patients treated with paricalcitol compared to
patients treated with calcitriol.65
In translational studies using our murine models of the
ABD described above,42,43 we have examined the ability of
therapy with calcitriol or 19-nor-1,25-dihydroxyvitamin D2
to rescue the ABD.66 Treatment with 10 and 20 ng/kg of
calcitriol or 50 and 100 ng/kg of paricalcitol for 12 weeks
following the induction of CKD and institution of a reduced
phosphorus diet produced an increase in the trabecular bone
volume, a reduction in osteoid surface, and an increase in
mineralizing surfaces in the paricalcitol-treated animals
compared to the calcitriol-treated animals. Calcitriol, but
not paricalcitol, increased osteoclast surfaces, suggesting,
perhaps, differential modulation of the VDR function in the
bone cell transcriptional machinery. These results were
recapitulated in the LDLR/ mice with CKD fed high-fat
diets,67 and, while further studies are required to clarify these
preliminary results, the possibility of differential modulation
of skeletal VDRs needs to be further investigated. The actions
of the skeletal VDR in our translational studies in CKD are
therefore in keeping with genetic studies of 1a(OH)ase
deficiency and VDR deficiency, to not inhibit but rather to
stimulate osteoblastic function. These results require further
analysis in the context of the ABD in dialysis patients and the
need to stimulate skeletal anabolism. Since we have
demonstrated that renal osteodystrophy contributes to
hyperphosphatemia in CKD, and that hyperphosphatemia
is a direct stimulus to osteogenic differentiation within the
vascular tunica media, stimulation of bone formation and
skeletal mineral deposition may have a lasting benefit in
avoiding the vascular calcification that otherwise complicates
CKD and ESKD. Overall therefore, newer vitamin D analogs
with more favorable properties based on novel scientific
insights may substantially improve mineral and skeletal
homeostasis in CKD.
REFERENCES
1. Bouillon R, Okamura WH, Norman AW. Structure–function relationships in
the vitamin D endocrine system. Endocr Rev 1995; 6: 200–257.
2. Sutton AI, MacDonald PN. Vitamin D: more than a ‘bone-a-fide’ hormone.
Molec Endocrinol 2003; 17: 777–791.
3. DeLuca HF. Overview of general physiologic features and functions of
vitamin D. Am J Clin Nutr 2004; 80(Suppl): 1689S–1696S.
4. Adams JS, Chen H, Chun R et al. Response element binding proteins and
intracellular vitamin D binding proteins: novel regulators of vitamin D
trafficking, action and metabolism. J Steroid Biochem Mol Biol 2004;
89–90: 461–465.
5. Jurutka PW, Whitfield GK, Hsieh J-C et al. Molecular nature of the vitamin
D receptor and its role in regulation of gene expression. Rev Endocr Metab
Disord 2001; 2: 203–216.
6. Norman AW, Mizwicki MT, Norman DPG. Steroid hormone rapid actions,
membrane receptors and a conformational ensemble model. Nat Rev
Drug Dis 2004; 3: 27–41.
7. Hendy GN, Goltzman D. Does calcitriol have actions independent from
the vitamin D receptor in maintaining skeletal and mineral homeostasis?
Curr Opin Nephrol Hypertens 2005; 14: 350–354.
8. Panda DK, Miao D, Tremblay ML et al. Targeted abalation of the
25-hydroxyvitamin D-1a-hydroxylase enzyme: evidence for skeletal,
reproductive, and immune dysfunction. Proc Natl Acad Sci USA 2001;
98: 7498–7503.
9. Dardenne O, Prud’homme J, Arabian A et al. Targeted inactivation of the
25-hydroxyvitamin D3-1a-hydroxylase gene (CYP27B1) creates an animal
model of pseudovitamin D-deficiency rickets. Endocrinology 2001; 142:
3135–3141.
10. Li YC, Pirro AE, Amling M et al. Targeted ablation of the vitamin D
receptor: an animal model of vitamin D-dependent rickets type II with
alopecia. Proc Natl Acad Sci USA 1997; 94: 9831–9835.
11. Yoshizawa T, Handa Y, Uematsu Y et al. Mice lacking the vitamin D
receptor exhibit impaired bone formation, uterine hypoplasia and
growth retardation after weaning. Nat Genet 1997; 16: 391–396.
12. Erben RG, Soegiarto DW, Weber K et al. Deletion of deoxyribonucleic acid
binding domain of the vitamin D receptor abrogates genomic and
nongenomic functions of vitamin D. Molec Endocrinol 2002; 16:
1524–1537.
13. Fraser D, Kooh SW, Kind HP et al. Pathogenesis of hereditary vitamin
D-dependent rickets: an inborn error of vitamin D metabolism involving
defective conversion of 25-hydroxyvitamin D to 1a,25-dihroxyvitamin D.
N Engl J Med 1973; 289: 817–822.
14. Beer S, Tieder M, Kohelet D et al. Vitamin D resistant rickets with alopecia:
a form of end organ resistance to 1,25-dihydroxyvitaminD. Clin Endocrinol
1981; 14: 395–402.
15. Panda DK, Miao D, Boliver I et al. Inactivation of the 25-hydroxyvitamin
D-1a-hydroxylase and vitamin D receptor demonstrates independent and
interdependent effects of calcium and vitamin D on skeletal and mineral
homeostasis. J Biol Chem 2004; 279: 16754–16766.
16. Li YC, Amling M, Pirro AE et al. Normalization by dietary means prevents
hyperparathyroidism, rickets and osteomalacia, but not alopecia in
vitamin D receptor-ablated mice. Endocrinology 1998; 139: 4391–4396.
17. Amling M, Priemel M, Holtzman T et al. Rescue of the skeletal phenotype
of vitamin D receptor-ablated mice in the setting of normal mineral ion
homeostasis: formal histomorphometric and biomechanical analyses.
Endocrinology 1999; 140: 4982–4987.
18. Dardenne O, Prud’homme J, Hacking SA et al. Correction of the
abnormal mineral ion homeostasis with a high-calcium,
high-phosphorus, high-lactose diet rescues the PDDR phenotype
of mice deficient for the 25-hydroxyvitamin D-1a-hydroxylase (CYP27B1).
Bone 2001; 32: 332–340.
19. Goltzman D, Miao D, Panda DK, Hendy GN. Effects of calcium and of the
vitamin D system on skeletal and calcium homeostasis: lessons from
genetic models. J Steroid Biochem Molec Biol 2004; 89–90: 485–489.
20. Xue Y, Karaplis AC, Hendy GN et al. Genetic models show that parathyroid
hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles
in postnatal mineral ion homeostasis and skeletal development. Hum
Molec Genet 2005; 14: 1515–1528.
21. Hoenderop JG, Dardenne O, Van Abel M et al. Modulation of renal Ca2+
transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D3 in
25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. FASEB J 2002;
16: 1398–1406.
22. Yagishita N, Yamamoto Y, Yoshizawa T et al. Aberrant growth plate
development in VDR/RXRg double null mutant mice. Endocrinology 2001;
142: 5332–5341.
23. Takeda S, Yoshizawa T, Nagai Y et al. Stimulation of osteoclast formation
by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor
(VDR) in osteoblastic cells: studies using VDR knockout mice.
Endocrinology 1999; 140: 1005–1008.
24. van Leeuwen JP, van Driel M, van den Bemd GJ, Pols HA. Vitamin
D control of osteoblast function and bone extracellular matrix
mineralization. Crit Rev Eukaryot Gene Expr 2001; 11: 199–226.
25. van Driel M, Pols HA, van Leeuwen JP. Osteoblast differentiation and
control by vitamin D and vitamin D metabolites. Curr Pharm Des 2004; 10:
2535–2555.
26. Reszka AA, Pun S, Freedman LP, Kimmel DB. The anabolic effects of
1,25(OH)2vitamin D3 revealed by combining with alendronate. Endocrine
Society Meeting, San Diego, June 2005 (abs OR51-4).
27. Xue Y, Goltzman D, Karaplis AC et al. PTH and 1,25-dihydroxyvitamin
D3 each independently exert skeletal anabolic effects and improve
mineral ion homeostasis in mice which are homozygous for both
the 1a-hydroxylase and PTH null alleles. J Bone Miner Res 2005;
20(Suppl1): S51.
222 Kidney International (2006) 69, 218–223
m i n i r e v i e w GN Hendy et al.: Mineral and skeletal regulation by vitamin D analogs
28. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with
predialysis chronic renal failure. J Clin Endocrinol Metab 1988; 67: 929–936.
29. Coen G, Mazzaferro S, Bonucci E et al. Treatment of secondary
hyperparathyroidism of pre dialysis chronic renal failure with low doses
of 1,25(OH)2D3: humoral and histomorphometric results. Miner Electrolyte
Metab 1986; 12: 375–382.
30. Bianchi ML, Colantonio G, Campanini F et al. Calcitriol and calcium
carbonate therapy in early chronic renal failure. Nephrol Dial Transplant
1994; 9: 1595–1599.
31. Mathias R, Salusky I, Harman W et al. Renal bone disease in pediatric and
young adult patients on hemodialysis in a children’s hospital. J Am Soc
Nephrol 1993; 3: 1938–1946.
32. Goodman WG, Salusky IB. Evolution of secondary hyperparathyroidism
during daily oral calcitriol therapy in pediatric renal osteodystrophy.
Contrib Nephrol 1991; 90: 189–195.
33. Hamdy NA, Kanis JA, Beneton NNC et al. Effect of alfacalcidol on natural
course of renal bone disease in mild to moderate renal failure. Br Med J
1995; 310: 358–363.
34. Slatopolsky E, Weerts C, Thielan J. Marked suppression of
secondary hyperparathyroidism by intravenous administration of
1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74:
2136–2143.
35. Salusky IB, Goodman WG, Norris KC et al. Bioavailability of calcitriol after
oral, intravenous and intraperitoneal doses in dialysis patients. In:
Norman AW, Shaefer K, Herrath D, Grigoleit H-G (eds), Berlin: Walter de
Gruyter, Vitamin D: Molecular, Cellular and Clinical Endocrinology 1988,
pp 83–84.
36. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral
versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
Kidney Int 1994; 45: 1710–1721.
37. Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus
intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996; 7:
488–496.
38. Salusky IB, Kuizon BD, Belin TR et al. Intermittent calcitriol therapy in
secondary hyperparathyroidism: a comparison between oral and
intraperitoneal administration. Kidney Int 1998; 54: 907–914.
39. Andress DL, Norris KC, Coburn JW et al. Intravenous calcitriol in the
treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J
Med 1989; 321: 274–279.
40. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone
in patients with secondary hyperparathyroidism after intermittent
calcitriol therapy. Kidney Int 1994; 46: 1160–1166.
41. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: Is there a
problem? J Am Soc Nephrol 2001; 12: 1978–1985.
42. Lund RJ, Davies MR, Brown AJ et al. Successful treatment of an adynamic
bone disorder with bone morphogenetic protein-7 in a renal ablation
model. J Am Soc Nephrol 2004; 15: 359–369.
43. Davies MR, Lund RJ, Mathew S et al. Low turnover osteodystrophy and
vascular calcification are amenable to skeletal anabolism in an animal
model of chronic kidney disease and the metabolic syndrome. J Am Soc
Nephrol 2005; 16: 917–928.
44. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum
phosphorus and calcium X phosphate product with mortality risk in
chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:
607–617.
45. Milliner DS, Zinsmeister AR, Lieberman E et al. Soft tissue calcification in
pediatric pateints with end-stage renal disease. Kidney Int 1990; 38:
931–936.
46. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular
disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112–S119.
47. Goodman WG, London G, Amann K et al. Vascular calcification in chronic
kidney disease. Am J Kidney Dis 2004; 43: 572–579.
48. Marchais SJ, Metivier F, Guerin AP et al. Association of
hyperphosphataemia with haemodynamic disturbances in end-stage
renal disease. Nephrol Dial Transplant 1999; 14: 2178–2183.
49. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in
end-stage renal diseases: impact on all-cause and cardiovascular
mortality. Nephrol Dial Transplant 2003; 18: 1731–1740.
50. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial
stiffness, and cardiovascular risk in end-stage renal disease. Hypertension
2001; 38: 938–942.
51. Blacher J, Safar ME, Guerin AP et al. Aortic pulse wave velocity index and
mortality in end-stage renal disease. Kidney Int 2003; 63: 1852–1860.
52. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid
arteriopathy in young adults with childhood-onset chronic renal failure.
Circulation 2002; 106: 100–105.
53. Doherty T, Tang W, Dascalos S et al. Ethnic origin and serum levels of
Ia25-dihydroxyvitamin D sub3 are independent predictors of coronary
calcium mass measured by electron-beam computed tomography.
Circulation 1997; 96: 1477–1481.
54. Watson KE, Abrolat ML, Malone LL et al. Active serum vitamin D levels are
inversely correlated with coronary calcification. Circulation 1997; 96:
1755–1760.
55. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is
accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000;
20: 317–327.
56. Price PA, June HH, Buckley JR et al. Osteoprotegerin inhibits artery
calcification induced by Warfarin and by Vitamin D. Arterioscler Thromb
Vasc Biol 2001; 21: 1610–1616.
57. Watson KE, Bostro¨m K, Ravindranath R et al. TGF-b1 and
25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify.
J Clin Invest 1994; 93: 2106–2113.
58. Jono S, Nishizawa Y, Shioi A et al. 1,25-dihydroxyvitamin D3 increases in
vitro vascular calcification by modulating secretion of endogenous
parathyroid hormone-related peptide. Circulation 1998; 98: 1302–1306.
59. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin
D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and
secretion. J Clin Invest 1989; 94: 728–732.
60. Brown AJ, Finch J, Grieff M et al. The mechanism for the disparate actions
of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133:
1158–1164.
61. Takahashi F, Finch J, Denda M et al. A new analog of 1,25-(OH)2D3,
19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland
growth in uremic rats without elevation of intestinal vitamin D receptor
content. Am J Kidney Dis 1997; 30: 105–112.
62. Monier-Faugere MC, Zhao G, Friedler RM et al. 22-Oxacalcitriol suppresses
secondary hyperparathyroidism without inducing low bone turnover in
dogs with renal failure. Kidney Int 1999; 55: 821–832.
63. Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol,
19-nor-1,25-(OH)2D2 suppresses parathyroid hormone secretion in
uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26:
852–860.
64. Sprague SM, Lerma E, McCormmick D et al. Suppression of parathyroid
hormone secretion in hemodialysis patients: comparison of paricalcitol
with calcitriol. Am J Kidney Dis 2001; 38: S51–S56.
65. Teng M, Wolf M, Lowrie EG et al. Survival of patients undergoing
hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;
349: 446–456.
66. Lund RJ, Hruska KA. Paricalcitol improves mineralization and bone
volume in a CKD model of the adynamic bone disorder (ABD) (abstract).
J Am Soc Nephrol 2004; 15: 735A.
67. Mathew S, Lund RJ, Strebeck F, Hruska KA. Effects of paricalcitol
therapy in the adynamic bone disorder (abstract). J Am Soc Nephrol 2005;
16: 32.
Kidney International (2006) 69, 218–223 223
GN Hendy et al.: Mineral and skeletal regulation by vitamin D analogs m i n i r e v i e w
